Evercore ISI Adjusts Price Target on AbbVie to $204 From $192
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie Is Maintained at Buy by Citigroup
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $209
AbbVie (ABBV) Gets a Buy From Piper Sandler
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating, Announces Target Price $206
AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline Uncertainties Warrants Hold Rating
Goldman Sachs Adjusts Price Target on AbbVie to $208 From $200
AbbVie Price Target Raised to $195.00/Share From $185.00 by B of A Securities
AbbVie Analyst Ratings
BofA Securities Initiates AbbVie(ABBV.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), AbbVie (ABBV) and Elevance Health (ELV)
Bernstein: First time covering eli lilly and co, gilead sciences and amgen, all with an "outperform large cap" rating.
AbbVie Is Maintained at Outperform by BMO Capital
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
AbbVie Analyst Ratings
Bernstein begins to focus on US pharmaceutical stocks, rating eli lilly and co (LLY.US) and others as "outperforming large cap".
Wells Fargo Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $205
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Ionis Pharmaceuticals (IONS) and Amicus (FOLD)